首页> 外文期刊>The Journal of Infectious Diseases >Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Dynamics during HCV Treatment in HCV/HIV Coinfection.
【24h】

Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Dynamics during HCV Treatment in HCV/HIV Coinfection.

机译:在HCV / HIV合并感染中进行HCV治疗期间,丙型肝炎病毒(HCV)和人类免疫缺陷病毒(HIV)动态。

获取原文
获取原文并翻译 | 示例
           

摘要

We studied hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics in 10 coinfected subjects in a trial of pegylated interferon-alpha2a (PEG-IFN) alone or combined with ribavirin (RBV), compared with IFN plus RBV for the treatment of HCV. Five subjects, 4 of whom were treated with PEG-IFN, achieved a sustained virological response, although it was delayed by >/=1 week in 3 subjects. The median treatment efficacy in blocking virion production was 99.7% in the PEG-IFN group and 60% with standard IFN. In 2 patients with detectable HIV loads before starting HCV study drugs, we observed a 1-log decrease in HIV RNA load. The estimated HCV virion half-life was longer in the HIV-coinfected subjects, which suggests that coinfection may contribute to a slower clearance of HCV. Although the early viral kinetics of coinfected subjects treated with PEG-IFN or IFN differ from those of singly infected subjects, the treatment response seems unaffected.
机译:我们在单独使用PEG化干扰素-α2a(PEG-IFN)或联合利巴韦林(RBV)的试验中,对10例合并感染的受试者进行了丙型肝炎病毒(HCV)和人免疫缺陷病毒(HIV)动态研究,比较了IFN加RBV治疗HCV。五名受试者(其中4名接受PEG-IFN治疗)获得了持续的病毒学应答,尽管3名受试者延迟了> / = 1周。 PEG-IFN组中阻断病毒粒子产生的中位治疗功效为99.7%,标准IFN为60%。在开始使用HCV研究药物之前,有2名可检测到HIV载量的患者中,我们观察到HIV RNA载量减少了1个对数。在感染了HIV的受试者中,估计的HCV病毒体半衰期更长,这表明合并感染可能会导致HCV清除速度减慢。尽管用PEG-IFN或IFN治疗的合并感染受试者的早期病毒动力学与单独感染的受试者不同,但治疗反应似乎并未受到影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号